$4.78
0.83% yesterday
Nasdaq, Jun 27, 10:09 pm CET
ISIN
US9216591084
Symbol
VNDA
Sector
Industry

Vanda Pharmaceuticals Inc. Stock price

$4.78
+0.45 10.39% 1M
-0.03 0.62% 6M
-0.01 0.21% YTD
-1.03 17.73% 1Y
-5.96 55.49% 3Y
-6.44 57.40% 5Y
-7.62 61.45% 10Y
-4.90 50.62% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.04 0.83%
ISIN
US9216591084
Symbol
VNDA
Sector
Industry

Key metrics

Basic
Market capitalization
$281.7m
Enterprise Value
$-54.3m
Net debt
$-336.0m
Cash
$340.9m
Shares outstanding
58.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.40 | 1.21
EV/Sales
negative | negative
EV/FCF
0.95
P/B
0.55
Financial Health
Equity Ratio
82.07%
Return on Equity
-3.51%
ROCE
-13.72%
ROIC
-
Debt/Equity
0.01
Financials (TTM | estimate)
Revenue
$201.4m | $232.3m
EBITDA
$-65.5m | $-38.0m
EBIT
$-72.5m
Net Income
$-44.3m | $-89.8m
Free Cash Flow
$-57.4m
Growth (TTM | estimate)
Revenue
13.37% | 16.86%
EBITDA
-204.84% | -13.94%
EBIT
-187.52%
Net Income
-804.91% | -374.92%
Free Cash Flow
-389.68%
Margin (TTM | estimate)
Gross
94.34%
EBITDA
-32.50% | -16.38%
EBIT
-35.98%
Net
-21.98% | -38.64%
Free Cash Flow
-28.50%
More
EPS
$-0.76
FCF per Share
$-0.97
Short interest
8.32%
Employees
368.00
Rev per Employee
$540.00k
Show more

Is Vanda Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Vanda Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:

Buy
78%
Hold
22%

Financial data from Vanda Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
201 201
13% 13%
100%
- Direct Costs 11 11
15% 15%
6%
190 190
16% 16%
94%
- Selling and Administrative Expenses 166 166
56% 56%
83%
- Research and Development Expense 89 89
13% 13%
44%
-65 -65
205% 205%
-33%
- Depreciation and Amortization 7.01 7.01
88% 88%
3%
EBIT (Operating Income) EBIT -72 -72
188% 188%
-36%
Net Profit -44 -44
805% 805%
-22%

In millions USD.

Don't miss a Thing! We will send you all news about Vanda Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vanda Pharmaceuticals Inc. Stock News

Neutral
PRNewsWire
18 days ago
WASHINGTON , June 10, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the first dose in the first-in-human clinical trial to evaluate the safety and tolerability of VCA-894A, an antisense oligonucleotide (ASO) therapeutic, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S). VCA-894A is being developed ...
Neutral
PRNewsWire
about one month ago
WASHINGTON , May 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, to be held in Scottsdale, Arizona, from May 27 through May 30, 2025. The following will be presented: May 27, 2025 Presentation Title: "Pharmacokinetic Results of Single-Dose and Multiple-Dose Bioe...
Neutral
PRNewsWire
about one month ago
WASHINGTON , May 16, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in investor meetings at the Mizuho Neuro & Ophthalmology Summit 2025 in New York City on Wednesday, May 21, 2025. About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of inno...
More Vanda Pharmaceuticals Inc. News

Company Profile

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Head office United States
CEO Mihael Polymeropoulos
Employees 368
Founded 2002
Website www.vandapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today